NPS Pharma Reports Second-Quarter 2014 Financial Results
Net global Gattex®/Revestive® sales of $22 million representing sequential growth of 22 percent
Full-year sales on track to meet guidance of $100 to $110 million
Advisory Committee meeting to review Natpara® BLA on September 12; PDUFA date of October 24
Conference call today at 5:00 PM ET
BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering innovative therapies that transform the lives of patients with rare diseases, today reported its results for the quarter ended June 30, 2014.
“Our gastrointestinal rare disease franchise continues to flourish with the success of Gattex in the U.S., including the expansion of our label to include long-term data from the STEPS 2 study”
NPS Pharma reported net global Gattex®/Revestive® sales of $22.0 million for the second quarter of 2014, compared to $4.8 million for the same period last year. NPS Pharma continues to expect to achieve full-year 2014 global net sales of $100 to $110 million representing more than 200 percent year-over-year growth.
“Our gastrointestinal rare disease franchise continues to flourish with the success of Gattex in the U.S., including the expansion of our label to include long-term data from the STEPS 2 study,” said Francois Nader, MD, president and chief executive officer of NPS Pharma. “Internationally, we are pleased with the progress we are making toward the commercialization of Revestive in key EU markets, and the execution of our development strategy in Japan.”
Dr. Nader added: “We continue to progress our high-potential endocrinology franchise toward commercialization. We are preparing for an FDA Advisory Committee meeting on September 12 as part of the Agency’s review of our Biologic License Application for Natpara and PDUFA date of October 24. Commercial readiness remains a key focus to prepare for the subsequent successful U.S. introduction of Natpara. We are also preparing to file our Marketing Authorization Application for Natpar, the European brand name for Natpara. And we expect to report preliminary data late this year or early next year from our recently initiated Phase 2a study of NPSP795 in autosomal dominant hypocalcemia.”
Net income (loss)
NPS Pharma reported net income of $2.0 million or $0.02 per diluted share for the second quarter of 2014 compared to a net loss of $12.4 million or $0.13 per diluted share for the same period last year.
The company’s revenues were comprised of net product sales for Gattex/Revestive and royalty revenues. Net sales were $22.0 million for the second quarter of 2014 compared to $4.8 million for the same period last year. In February 2013, NPS Pharma launched and initiated sales of Gattex in the U.S.
Royalty revenues were $34.2 million for the second quarter of 2014 compared to $31.7 million for the same period last year. NPS earns royalties on (i) Amgen’s sales of Sensipar®/Mimpara® (cinacalcet HCl), (ii) Kyowa Hakko Kirin’s sales of REGPARA® (cinacalcet HCl), and (iii) Janssen Pharmaceuticals’ sales of NUCYNTA® (tapentadol) and NUCYNTA® ER (tapentadol extended-release tablets).
The components of royalties are summarized as follows:
Three months ended
|Six months ended|
|June 30,||June 30,|
|NUCYNTA and other||0.7||0.8||1.3||1.5|
On August 15, 2014, the company will receive a cash payment of $23.6 million for the Sensipar/Mimpara royalties earned during the second quarter of 2014. The remaining $8.0 million of Sensipar/Mimpara royalties will be retained to repay a royalty advance received in August 2011 from Amgen. At June 30, 2014, NPS Pharma had $40.6 million in non-recourse debt secured by its Sensipar royalties.
Research and development
Research and development expenses were $21.2 million for the second quarter of 2014 as compared to $30.9 million for the same period last year. The decline was attributable to a decrease in costs related to the production of pre-approval Natpara inventory.
Selling, general and administrative
Selling, general and administrative expenses were $26.4 million for the second quarter of 2014 as compared to $14.5 million for the same period last year. The increase in selling, general and administrative expenses was primarily due to commercial activities related to Gattex/Revestive and pre-launch activities for Natpara.
Interest expense was $3.6 million for the second quarter of 2014 compared to $3.0 million for the same period last year. Interest expense was largely attributable to non-recourse debt secured by the company’s Sensipar/Mimpara, rhPTH 1-84, and REGPARA revenues.
Cash and investments
The company’s cash, cash equivalents, and marketable investment securities were approximately $169.5 million at June 30, 2014 compared to $180.5 million at December 31, 2013.
At June 30, 2014, all debt on the company’s balance sheet is non-recourse and secured solely by royalties related to Sensipar/Mimpara, REGPARA, and worldwide sales, excluding Israel, of PTH 1-84. After repayment of these obligations, the cash flows from these royalties will revert to NPS Pharma in accordance with the terms set forth in each agreement.
The following table reflects the company’s non-recourse debt at June 30, 2014 and December 31, 2013:
|June 30, 2014||December 31, 2013|
|PTH 1-84-secured (worldwide, excluding Israel)||42.8||42.8|
|Total non-recourse debt||116.8||132.4|
|Less current portion||9.3||8.8|
|Total long-term non-recourse debt||$107.5||$123.6|
2014 Financial Guidance
The company is reiterating its full-year 2014 net sales guidance of $100 to $110 million.
The company continues to expect full-year 2014 operating expenses, excluding the impact of share-based compensation and cost of goods sold, to be between $180 and $200 million. NPS Pharma reported share-based compensation of $7.6 million for the six months ended June 30, 2014.
The foregoing financial guidance comprises projections based on numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward-looking statements, please see the disclosure notice below.
Conference Call Information
NPS will host a conference call beginning today at 5:00 p.m. Eastern Time. To participate in the conference call, dial (800) 510-9691 and use pass code 89848006. International callers may dial +1 (617) 614-3453, using the same pass code. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the NPS website, http://www.npsp.com.
For those unable to participate in the live call, a replay will be available at (888) 286-8010, with pass code 42267576, until midnight Eastern Time, August 20, 2014. International callers may access the replay by dialing +1 (617) 801-6888, using the same pass code. The webcast will also be available through the NPS website for the same period.
About NPS Pharma
NPS Pharma is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases. The current therapeutic areas of focus for NPS Pharma are rare gastrointestinal disease and endocrine disorders. These include Short Bowel Syndrome, a potentially fatal gastrointestinal disorder in which patients may have to rely on parenteral nutrition for their survival; Hypoparathyroidism, a complex endocrine disorder in which the parathyroid glands are either absent or damaged, and the body produces insufficient or no parathyroid hormone; and Autosomal Dominant Hypocalcemia, an ultra-rare, genetic disorder of calcium homeostasis caused by mutations of the calcium-sensing receptor gene. NPS Pharma is actively seeking in-licensing opportunities to develop new therapies for a broad range of rare diseases, and complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals and Kyowa Hakko Kirin. NPS Pharma has operations in the U.S., Canada, Europe, Latin America and Japan. Learn more at: www.npsp.com
“NPS Pharma” and “NPS Pharmaceuticals” are the company's trademarks.
Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on the company's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward looking statements include, but are not limited to, statements concerning the company’s future financial performance and plans for the commercialization of its products, beliefs or expectations regarding our products in development, including statements regarding regulatory milestones, statements concerning the company’s plans for international expansion, beliefs or expectations regarding potential revenue and earnings from product sales, including beliefs regarding our ability to grow sales, expectations regarding the market size for our products, including those in development, and beliefs or expectations regarding our operating expenses. Risks associated to the company's business include, but are not limited to, the risks associated with any failure by the company to successfully commercialize Gattex/Revestive (teduglutide [rDNA origin]) for injection, including the risk that physicians and patients may not see the advantages of Gattex/Revestive and may therefore be reluctant to utilize the product, the risk that private and public payers may be reluctant to cover or provide reimbursement for Gattex, risks related to regulatory and reimbursement approvals for Natpara/Natpar (recombinant human parathyroid hormone 1-84 (rhPTH 1-84)), the risks associated with the company's strategy, global macroeconomic conditions, the impact of changes in management or staff levels, the effect of legislation effecting healthcare reform in the United States, as well as other risk factors described in the company's periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Form 10-Qs. All information in this press release is as of the date of this press release and NPS undertakes no duty to update this information, whether as a result of new information, future events or otherwise.
NPS Pharmaceuticals and Subsidiaries
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
|Three Months Ended||Six Months Ended|
|June 30,||June 30,|
|Product sales, net||$21,955||$4,801||$39,826||$5,455|
|Cost of sales||2,737||473||4,614||538|
|Research and development||21,151||30,888||41,708||46,583|
|Selling, general and administrative||26,449||14,465||51,003||28,670|
|Total operating expenses||47,600||45,353||92,711||75,253|
|Operating income (loss)||5,790||(9,321||)||2,842||(13,852||)|
|Other (expense) income:|
|Interest income, net||103||58||224||113|
|Total other expense, net||(3,535||)||(3,064||)||(7,152||)||(6,329||)|
|Income (loss) before income tax expense||2,255||(12,385||)||(4,310||)||(20,181||)|
|Income tax expense||263||4||274||4|
|Net income (loss)||$1,992||($12,389||)||($4,584||)||($20,185||)|
Net income (loss) per common and potential common share:
|Weighted average common and potential common share:|
NPS Pharmaceuticals and Subsidiaries
Condensed Consolidated Balance Sheets
|June 30,||December 31,|
|Cash, cash equivalents and marketable investment securities||$169,482||$180,474|
|Other current assets||8,447||7,001|
|Property and equipment, net||4,850||4,402|
|Debt issuance costs, net||284||338|
|Liabilities and Stockholders’ Equity:|
|Accounts payable and accrued expenses||$33,770||$33,117|
|Current portion of non-recourse debt*||9,270||8,752|
|Non-recourse debt, less current portion*||107,477||123,635|
|Other long-term liabilities||7,443||5,283|
|Common stock and additional paid-in capital||1,156,385||1,127,523|
|Accumulated other comprehensive income||(107||)||56|
|Total stockholders' equity||129,005||104,890|
|Total liabilities and stockholders' equity||$286,965||$292,222|
* Non-recourse debt secured by Sensipar®/Mimpara®, rhPTH 1-84, and REGPARA® revenue